Edwards Lifesciences Q3 2026 Results: Net Income $308M, Up 5.6% YoY
For the nine months ended September 30, 2026, Edwards Lifesciences reported net sales of $5.11 billion, a 13.5% increase over the prior year. Despite higher revenue, net income attributable to the corporation decreased to $930.1 million from $982.3 million, primarily due to a significant $163.6 million impairment loss and higher income tax provisions.
- Key figure
- Net income $308M · +5.6% YoY